← FDA Drug Approvals (Drugs@FDA)

ORBACTIV

NDA · New Drug Application · Sponsor: MELINTA THERAP · Approved 2014-08-06

Drug application

FDA Application #

NDA206334

Application type

New Drug Application

Brand name

ORBACTIV

Generic name

ORITAVANCIN

Active ingredients

ORITAVANCIN DIPHOSPHATE

Dosage form

POWDER

Route

INTRAVENOUS

Marketing status

Prescription

Sponsor

MELINTA THERAP

Manufacturer

Melinta Therapeutics, LLC

First approval

2014-08-06

Source

Authoritative

Drugs@FDA application overview

Machine

JSON-LD · Markdown